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Numerous studies show efflux as a universal bacterial mechanism contributing to
antibiotic resistance and also that the activity of the antibiotics subject to efflux can
be enhanced by the combined use of efflux inhibitors. Nevertheless, the contribution
of efflux to the overall drug resistance levels of clinical isolates of Mycobacterium
tuberculosis is poorly understood and still is ignored by many. Here, we evaluated
the contribution of drug efflux plus target-gene mutations to the drug resistance levels
in clinical isolates of M. tuberculosis. A panel of 17 M. tuberculosis clinical strains
were characterized for drug resistance associated mutations and antibiotic profiles
in the presence and absence of efflux inhibitors. The correlation between the effect
of the efflux inhibitors and the resistance levels was assessed by quantitative drug
susceptibility testing. The bacterial growth/survival vs. growth inhibition was analyzed
through the comparison between the time of growth in the presence and absence of
an inhibitor. For the same mutation conferring antibiotic resistance, different MICs were
observed and the different resistance levels found could be reduced by efflux inhibitors.
Although susceptibility was not restored, the results demonstrate the existence of a
broad-spectrum synergistic interaction between antibiotics and efflux inhibitors. The
existence of efflux activity was confirmed by real-time fluorometry. Moreover, the efflux
pump genes mmr, mmpL7, Rv1258c, p55, and efpA were shown to be overexpressed
in the presence of antibiotics, demonstrating the contribution of these efflux pumps
to the overall resistance phenotype of the M. tuberculosis clinical isolates studied,
independently of the genotype of the strains. These results showed that the drug
resistance levels of multi- and extensively-drug resistant M. tuberculosis clinical strains
are a combination between drug efflux and the presence of target-gene mutations,
a reality that is often disregarded by the tuberculosis specialists in favor of the
almost undisputed importance of antibiotic target-gene mutations for the resistance in
M. tuberculosis.
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INTRODUCTION
The development of mutations in the genes associated with
the resistance to the antituberculosis drugs have long been
considered the sole cause of resistance in tuberculosis (Zhang
and Yew, 2009; da Silva and Palomino, 2011). Nevertheless,
Mycobacterium tuberculosis also presents intrinsic drug
resistance, mainly attributed to the unusual structure of its
mycolic acid-containing cell wall combined with effective efflux
mechanisms (Jarlier and Nikaido, 1994; da Silva et al., 2011).
The balance between the reduced permeability of the cell wall
that acts synergistically with the activity of efflux pumps and the
increased expression of genes that code for those efflux pumps
is believed to constitute the first step for the development and
stabilization of drug resistant phenotypes (Machado et al., 2012;
Schmalstieg et al., 2012; Viveiros et al., 2012; da Silva et al., 2016).
Previous studies have demonstrated the contribution of efflux
mechanisms to antibiotic resistance in M. tuberculosis revealing
the presence of several putative efflux pumps of different classes
involved in the transport of different compounds (Viveiros et al.,
2012; Black et al., 2014; da Silva et al., 2016; Supplementary Table
1). The best-represented families of efflux transporters in M.
tuberculosis are the ATP-binding cassette (ABC) superfamily and
themajor facilitator superfamily (MFS) followed by the resistance
nodulation cell division (RND) superfamily of transporters.
The most well-characterized ABC transporters showed to be
involved in the transport of multiple drugs are the efflux pumps
DrrAB, Rv2686c-2687c-2688c, Rv1456c-Rv1457c-Rv1458c, and
the Rv1217c-1218c (Choudhuri et al., 2002; Pasca et al., 2004;
Balganesh et al., 2010; Hao et al., 2011; Wang et al., 2013).
Among the MFS, the most studied efflux pumps are the
Rv1258c (Tap-like), associated with resistance to tetracycline,
rifampicin and clofazimine (Siddiqi et al., 2004; Ramón-García
et al., 2012); the P55, that confer resistance to aminoglycosides,
tetracycline, rifampicin and clofazimine (da Silva et al., 2001;
Ramón-García et al., 2009; Bianco et al., 2011); and the EfpA
efflux transporter that is associated with resistance to isoniazid,
fluoroquinolones and dyes (Doran et al., 1997). The RND efflux
pumps are associated with the transport of a wide variety of
substrates in M. tuberculosis (Bailo et al., 2015). Among these,
it was shown that the MmpL7 protein confer low-level isoniazid
resistance when overexpressed (Pasca et al., 2005; Machado et al.,
2012). Likewise, the overexpression of theMmpS5-MmpL5 efflux
transporter was associated with the resistance of M. tuberculosis
to azoles (Milano et al., 2009) and with the acquired resistance
to bedaquiline, the diarylquinoline recently approved for the
treatment of multidrug resistant tuberculosis (Andries et al.,
2014). The Mmr efflux transporter is the only efflux pump
from the small multidrug resistance (SMR) family present in
the M. tuberculosis genome and is associated with the reduced
susceptibility of M. tuberculosis to dyes and antibiotics such as
isoniazid, erythromycin, and fluoroquinolones (De Rossi et al.,
1998; Rodrigues et al., 2013).
The overexpression of these and other efflux pumps is
believed to decrease the intracellular levels of the antibiotics
and prevent the drug to reach its cellular target, allowing the
emergence of a subpopulation presenting high-level resistance
(Machado et al., 2012; Schmalstieg et al., 2012). Noteworthy,
efflux-basedmechanisms were recently implicated in the intrinsic
resistance to bedaquiline, and the efflux system MmpS5-MmpL5
was identified as being responsible for the non-target based
resistance (Andries et al., 2014). In this sense, an approach
to overcome the emergence of this efflux-mediated drug
resistance can be the combined use of efflux inhibitors and
antibiotics.
Up to now, a number of compounds have been shown as
potential inhibitors of theM. tuberculosis efflux systems (Viveiros
et al., 2012; da Silva et al., 2016). Among these, the most
studied are the ion channel blockers like the phenothiazines
thioridazine and chlorpromazine and the phenylalkylamine
verapamil (Viveiros et al., 2012; da Silva et al., 2016; Machado
et al., 2016). The mechanism by which these compounds
are active against M. tuberculosis is not fully understood,
however, some hypothesis for their mode action have been
raised and discussed (Viveiros et al., 2012; Adams et al.,
2014; Rayasam and Balganesh, 2015). Verapamil, a calcium
channel blocker in eukaryotic cells, is able to decrease the
minimum inhibitory concentrations (MICs) of antituberculosis
drugs in M. tuberculosis clinical strains (Louw et al., 2011;
Machado et al., 2012; Coelho et al., 2015), accelerates the
bactericidal and sterilizing activities of antituberculosis drugs
in a mouse model (Gupta et al., 2013), potentiates the activity
of bedaquiline (Gupta et al., 2014), and inhibits macrophage-
induced antibiotic tolerance of M. tuberculosis (Adams et al.,
2011, 2014). Likewise, the phenothiazines have shown similar
activities in spite of their toxicity compared to verapamil and
other efflux inhibitors (Ordway et al., 2003; Viveiros et al., 2012).
The phenothiazines disturb the calcium-calmodulin transport
and signaling pathways (Salih et al., 1991; Pluta et al., 2011),
cause modifications at the level of the bacterial membrane and
on nucleic acid stability (Pluta et al., 2011; Thorsing et al.,
2013), inhibit the type II NADH-ubiquinone dehydrogenase
and other electron-transport chain enzymes (Weinstein et al.,
2005), and have significant activity against M. tuberculosis in
vitro, ex vivo, and in murine models (Ordway et al., 2003;
Machado et al., 2012; Dutta et al., 2014; Singh and Sharma,
2014; Coelho et al., 2015). Recently, we observed that these
ion channel blockers lead to a significant decrease in the
intracellular mycobacterial load as result of the inducement of
phagosome acidification and activation of lysosomal hydrolases
(Machado et al., 2016). The potential use of efflux inhibitors
in combination with antibiotics may constitute an important
alternative as adjuvants of the antituberculosis conventional
therapeutic regimen. Previously, we have demonstrated that
multidrug resistance and in particular the development of
resistance to isoniazid develops in M. tuberculosis laboratory
strains associated with the genetic and physiological activity
of efflux pumps (Machado et al., 2012). Nonetheless, two
questions remain answered—the role of the efflux systems in M.
tuberculosis resistant strains that already carry mutations in the
drug target genes and how do they respond to the drug pressure
despite the presence of these mutations—a contribution to the
overall resistance level poorly understood and still disregarded
by many.
The main purpose of this study is to assess the role played by
the efflux systems in M. tuberculosis strains that carry mutations
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in the drug target genes. In order to do this, we have studied
the contribution of efflux to the overall resistance levels toward
antituberculosis drugs in a panel ofmono-, multi- and extensively
drug resistant (MDR/XDR) M. tuberculosis clinical isolates
from two geographical distinct areas baring well-known and
characterized drug-resistance associated mutations. To quantify
the role of efflux in these strains and establish clinical correlation,
we performed quantitative drug susceptibility testing (qDST)
and investigated the time to detection (TTD) of growth of
each strain for first- and second-line antituberculosis drugs in
the presence and absence of the efflux inhibitors verapamil,
thioridazine, and chlorpromazine. The results obtained revealed
that the addition of efflux inhibitors enhanced the effect of the
antituberculosis drugs independently of the genotype of the M.
tuberculosis strains. Here we have demonstrated the effectiveness
of a synergistic combination of drugs with the conventional
therapy despite the presence of a mutation conferring resistance
that showed to be beneficial since it reduced the resistance level of
the strain. Moreover, these results strongly support the relevance
of these inhibitors as adjuvants in tuberculosis chemotherapy.
MATERIALS AND METHODS
Strains
The strains selected for this study are described in Table 1
and were isolated from Portuguese and Brazilian tuberculosis
patients as part of the routine mycobacteriology laboratory
services provided by Universidade NOVA de Lisboa (Lisboa,
Portugal) and Universidade Federal do Rio Grande (Porto
Alegre, Brazil) to the local hospitals. Since the main objective of
this work was to analyze the interplay between the mutational
resistance and the efflux activity, the strains were selected
based on their drug resistance pattern in order to include pan-
susceptible, isoniazid monoresistant, rifampicin monoresistant,
ofloxacin monoresistant, poly-drug resistant (resistant to more
than one first-line antituberculosis drugs other than both
isoniazid and rifampicin), MDR (resistant at least to isoniazid
and rifampicin), and XDR (MDR plus resistance to any
fluoroquinolone and amikacin, kanamycin, or capreomycin)
strains. The H37Rv ATCC27294T reference strain was obtained
from the American Type Culture Collection (Virginia, USA),
and used as control. Given the retrospective nature of the work
involving only anonymized bacterial isolates, informed consent
was not required for this study.
Drug Susceptibility Testing and MIC
Determination
First- and second-line drug susceptibility testing (DST) and MIC
determination were done using the MGIT 960 system using the
Epicenter V5.80A software and the TB eXIST module (Becton
Dickinson, Diagnostic Systems, Sparks, MD, USA). The critical
concentrations used for DST were as follows: isoniazid, 0.1
µg/ml; rifampicin, 1 µg/ml; streptomycin, 1 µg/ml; ethambutol,
5 µg/ml; amikacin, 1 µg/ml; capreomycin, 2.5 µg/ml; and
ofloxacin, 1 µg/ml. The results were interpreted as follows: at
the time of positivity of the proportional control [Growth units
(GU) = 400] if the tubes containing the drugs were GU > 100,
they were considered resistant to that concentration. If the GU of
TABLE 1 | Categorization of the M. tuberculosis strains studied according to their lineage, resistance pattern, and phenotype.
Strain Isolation date Lineage* Resistance pattern Phenotype
H37Rv – H37Rv None Susceptible
MtbPT1 2006 LAM9—Orphan None Susceptible
MtbPT2 2008 Unknown—SIT150 None Susceptible
MtbPT3 2003 T1 INH Monoresistant to INH
MtbPT4 2009 LAM1 INH Monoresistant to INH
MtbPT5 2003 LAM1 RIF Monoresistant to RIF
MtbPT6 2005 LAM1 RIF Monoresistant to RIF
MtbBR1 2009 EAI1-SOM OFX Monoresistant to OFX
MtbBR2 2007 Beijing INH, OFX Poly-drug resistant
MtbBR3 2010 H3 INH, RIF MDR
MtbBR4 2011 T1 INH, RIF MDR
MtbBR5 2011 T2 INH, RIF MDR
MtbPT7 2009 LAM1—Lisboa3& INH; RIF MDR
MtbBR6 2008 Beijing INH, RIF, AMK, CAP MDR
MtbPT8 2011 Beijing INH; RIF; AMK; CAP MDR
MtbPT9 2009 LAM1—Lisboa3& INH; RIF; AMK; CAP; OFX XDR
MtbPT10 2009 LAM4—Q1& INH; RIF; AMK; CAP; OFX XDR
MtbPT11 2012 LAM4—Q1& INH; RIF; AMK; CAP; OFX XDR
*Spoligotype lineages/sublineages according to the international spoligotype database SITVITWEB rules. “Unknown” designates patterns with signatures that do not belong to any of
the major lineages defined in the SITVITWEB database. &Lisboa3 and Q1 M. tuberculosis strains were clustered by 24-loci MIRU-VNTR analysis. AMK, amikacin; CAP, capreomycin;
EAI, East-African-Indian; H, Haarlem. INH, isoniazid; LAM, Latin American-Mediterranean; MDR, multidrug resistant; OFX, ofloxacin; RIF, rifampicin; SIT, spoligotype international type;
XDR, extensively drug resistant.
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the tube containing the drugs were <100 they were considered
susceptible (Springer et al., 2009; Cambau et al., 2015). In these
assays, the critical concentration of the antituberculosis drugs are
defined as the concentration that is required to eliminate more
than 99% of the population of a control strain that never has
been in contact with the drug. A strain is considered susceptible
to a given drug tested at their critical concentration if, among
the population, the proportion of resistant cells is <1% (critical
proportion). The strain is considered resistant when the number
of drug-resistant bacteria present in the drug-containing tube is
>1%, when compared with the drug-free proportional growth
control.
MIC determination of the antibiotics and efflux inhibitors
was done within the MGIT 960 system and the growth
monitored with the Epicenter V5.80A software as previously
described (Machado et al., 2016). The MIC was considered as
the lowest concentration with GU < 100 when the drug-free
proportional control tube reached a GU = 400. The lowest
concentration tested corresponded to the critical concentration
of each antibiotic (susceptibility breakpoint).
An absolute growth control (undiluted) was included in every
assay to monitor the normal growth of each strain. In this study,
the TTD for positivity of the drug-free proportional control
varied between 8 and 16 days depending on the strains. DST and
MIC determination were performed at least in duplicate and the
final value was given as the result of two concordant values.
Quantitative Drug Susceptibility Testing
qDST of the antibiotics was conducted using the MGIT 960
system and the growth monitored with the Epicenter V5.80A
software and the TB eXIST module (Becton Dickinson). The
test was performed and interpreted according to the protocol
previously described (Cambau et al., 2015). Isoniazid was tested
at 0.1, 1, 3, and 10 µg/ml, rifampicin and amikacin at 1, 4, and
20 µg/ml, capreomycin at 2.5, 5, and 25 µg/ml, and ofloxacin
at 1, 2, and 10 µg/ml. Antibiotics for which the strains were
resistant at the highest concentration tested by qDST, were
further tested at higher concentrations by MIC determination.
The interpretation of the results was done as described above. The
antibiotic resistance levels were quantified as follows: isoniazid
low-level resistance when resistant (R) at 0.1 and susceptible (S)
at 1 µg/ml; isoniazid high-level resistance when R ≥ 1 µg/ml;
rifampicin and amikacin low-level resistance when R at 4 and S
at 20 µg/ml; rifampicin and amikacin high-level resistance when
R ≥ 20 µg/ml; capreomycin low-level resistance when R at 5
and S at 25 µg/ml; capreomycin high-level resistance when R
≥ 25 µg/ml; ofloxacin low-level resistance when R at 1 and S
at 2 µg/ml; ofloxacin high-level resistance when R ≥ 2 µg/ml
(Cambau et al., 2015). The evaluation of bacterial growth/survival
vs. growth inhibition was done by the comparison between the
TTD, defined as the time from the start of incubation to the
positivity signal of growth (Diacon et al., 2014; Bowness et al.,
2015), of a given strain in the presence and absence of an inhibitor
(1TTD). To obtain the degree of potentiation of each compound
on the antibiotic activity, the 1TTD was normalized against the
control tube with no inhibitor. qDST was performed at least
in duplicate and the final value was given as the result of two
concordant values.
Detection of Mutations Associated with
Resistance
Genomic DNA was isolated using the QIAamp DNA mini
kit (QIAGEN, GmbH, Hilden, Germany) according to the
manufacturer’s instructions. The most common mutations
in inhA regulatory region, and katG, gyrA, and rrs genes
were studied using the Genotype MTBDRplus and MTBDRsl
(Hain Lifescience GmbH, Nehren, Germany) according to the
manufacturer’s instructions. Genomic analysis of the complete
inhA, katG, and tlyA genes and eis promoter region was
performed by PCR amplification and DNA sequencing using the
primers described elsewhere (Feuerriegel et al., 2009; Machado
et al., 2013; Perdigão et al., 2013). The annealing temperatures
were 60◦C for inhA, 62◦C for katG, 56◦C for eis, and 55◦C for
tlyA.
Evaluation of Ethidium Bromide
Accumulation and Efflux
Real-time detection of efflux activity was performed with a
semi-automated fluorometric method using a Rotor-Gene 3000
thermocycler (Corbett Research, Sydney, Australia) (Paixão
et al., 2009; Viveiros et al., 2010; Rodrigues et al., 2015).
The assays were performed as previously described (Machado
et al., 2012). M. tuberculosis strains were grown in 10 ml
of Middlebrook 7H9 (Difco, Madrid, Spain) supplemented
with 10% OADC (oleic acid, albumin, dextrose, catalase;
Becton and Dickinson) with 0.05% Tween 80 at 37◦C until
an OD600 nm(OD600) of 0.8. The cells were collected by
centrifugation at 2940 × g for 3 min, the supernatant discarded,
the pellet washed in PBS and centrifuged again in the same
conditions.
Ethidium Bromide Accumulation Assays
For the ethidium bromide accumulation assays, the pellet was
resuspended in PBS and the OD600 adjusted to 0.8. To determine
the concentration of ethidium bromide that establishes the
equilibrium between efflux and influx, the cells were incubated
with different concentrations of ethidium bromide (0.625–5
µg/ml). The assays were conducted at 37◦C in a Rotor-Gene 3000
(530; 585 nm) and the equilibrium concentration determined for
each strain as the concentration that promoted a plateau of no
more than 10% of relative fluorescence units during the 60 min
of the assay. To evaluate the effect of the efflux inhibitors on the
accumulation of ethidium bromide, the assays were performed as
described above with the exception that each inhibitor was added
to the buffer solution at half MIC and ethidium bromide was used
at the equilibrium concentration (determined for each strain).
The inhibitory activity of the compounds was determined by the
calculation of the relative final fluorescence (RFF; Machado et al.,
2011) which is a measure of how effective the compound is on the
inhibition of ethidium bromide efflux (at a given concentration)
by comparison of the final fluorescence at the last time point
(60 min) of the treated cells with the cells in presence of only
ethidium bromide. An index of activity above zero indicated
that the cells accumulate more ethidium bromide under the
condition used than those of the control (non-treated cells).
Negative RFF values indicated that the treated cells accumulated
less ethidium bromide than those of the control condition.
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Values above 1 in the presence of the efflux inhibitors indicated
enhanced accumulation of ethidium bromide inside the cells.
The experiments were done in triplicate and the RFF values
are presented as the average of three independent assays plus
standard deviation (±SD).
Ethidium Bromide Efflux Assays
For the ethidium bromide efflux assays, the pellet was
resuspended in PBS and the OD600 adjusted to 0.4. The
cell suspensions were exposed to ethidium bromide at the
equilibrium concentration determined above, in the presence
of verapamil at half MIC for 1 h at room temperature. The
cells were then pelleted by centrifugation and resuspended in
new buffer with and without 0.4% glucose in the presence and
absence of half MIC of verapamil and the fluorescence measured
as described above. Data was normalized by comparing the
relative fluorescence units obtained under the conditions that
promote efflux (presence of glucose and absence of verapamil)
with the relative fluorescence units from the control in which
there is no efflux (presence of verapamil and no glucose). The
RFF corresponds to the ratio of the fluorescence that remains per
unit of time, relatively to the cells in presence of the inhibitor.
RT–qPCR Analysis of Putative Efflux Pumps
Strains were grown in MGIT tubes (mycobacteria growth
indicator tubes; Becton Dickinson) for the MGIT 960 system
in the presence of half MIC of each antibiotic as follows:
MtbPT3 was exposed to isoniazid; MtbPT5 was exposed to
rifampicin; MtbBR1 was exposed to ofloxacin; H37Rv, MtbPT7,
and MtbPT11 were exposed to isoniazid or rifampicin. Total
RNA was extracted using a GTC/Trizol method as previously
described (Machado et al., 2016). The relative expression level
of the efflux pump genes mmpL7, p55, efpA, mmr, Rv1258c, and
Rv2459was analyzed by RT-qPCR. The primer sets and sequences
of oligonucleotides used are described elsewhere (Machado et al.,
2012). RT-qPCR assay was performed in a Rotor-Gene 3000
thermocycler and followed the protocol recommended for use
with the QuantiTect SYBR Green RT-PCR Kit (QIAGEN) with
the following amplification program: reverse transcription for
30 min at 50◦C; initial activation step for 15 min at 95◦C;
35 cycles of denaturation at 94◦C for 30 s, annealing at 52◦C
for 30 s and extension at 72◦C for 30 s; a final extension
step at 72◦C for 5 min; and an additional step at 50◦C for
15 s followed by melt analysis (50–99◦C). The determination
of the relative mRNA expression level was performed using
the comparative quantification cycle (Cq) method (Livak and
Schmittgen, 2001). The relative expression of each target gene
was determined by comparison of the relative quantity of the
respective mRNA in the presence of the antibiotic to the non-
exposed condition. Each strain was assayed in triplicate using
total RNA obtained from three independent cultures. A relative
expression level equal to 1 indicated that the expression level
was identical to the unexposed strain. Genes showing expression
levels above one were considered to be overexpressed. Genes
showing expression levels above two were considered to be
significantly overexpressed. Normalization of the mRNA levels
was done using theM. tuberculosis 16S rDNA as internal control
for each experiment and presented as the mean-fold change
(±SD) compared with the control.
MIRU-VNTR and Spoligotyping Analysis
Mycobacterial Interspersed Repetitive Unit—Variable Number
of Tandem Repeats (MIRU-VNTR) genotyping was performed
by multiplex PCR amplification of 24-loci MIRU-VNTR, as
described previously (Supply et al., 2006). Spoligotyping was
performed as per Kamerbeek et al. (1997). The genotype of
these strains was analyzed using the MIRU-VNTRplus web
application (Allix-Béguec et al., 2008; Weniger et al., 2010) and
the SITVITWEB database (Demay et al., 2012).
Data Analysis
Data analysis was carried out using the Student’s t-test. A ∗P <
0.05 was considered statistically significant and highly significant
when ∗∗P < 0.01 and ∗∗∗P < 0.001 (two-tailed tested).
RESULTS
Correlation between the Phenotype and
Mutations Associated with Antibiotic
Resistance
Firstly, to establish a correlation between the phenotypic
drug resistance level and the presence of resistance
associated mutations, we searched for mutations in the
genes associated with drug resistance to the antibiotics studied
(Table 2).
The three pan-susceptible strains showed no mutation in any
of the genes evaluated. Resistance to isoniazid was associated
with mutations in the katG and inhA genes which are in
accordance with published data (Cambau et al., 2015; Domínguez
et al., 2016). MtbPT3 showed the S315T mutation in katG
and MtbPT4 presented the C-15T substitution in the inhA
promoter region. Among the nine MDR strains, five harbored
mutations in katG, of which four had the S315T mutation
and one has a rare mutation at codon 735. The remaining
four strains harbored double mutations in inhA. The double
mutations C-15T/S94A were detected in strains MtbPT7 and
MtbPT9 and the pair C-15T/I194T was detected inMtbPT10 and
MtbPT11.
In respect to rifampicin resistance, all MDR strains and
the two rifampicin monoresistant strains showed the mutation
S531L in rpoB. This is the most common mutation found in
clinical isolates resistant to rifampicin (Cambau et al., 2015;
Domínguez et al., 2016). Strain MtbBR2 carries the mutation
D516Y in rpoB but it was found susceptible to rifampicin.
Although was not our aim to evaluate susceptible strains,
MtbBR2 was initially found to be resistant to rifampicin
at 1 µg/ml (critical concentration). After re-testing MtbBR2
for rifampicin resistance, it was found susceptible, although
with a MIC close to the breakpoint, and was reclassified
as poly-drug resistant. The role of the mutation D516Y in
rifampicin resistance is not clear. It has been reported by
others to be associated with high-level rifampicin resistance
(Cambau et al., 2015), low-level resistance (Williams et al., 1998;
Zaczek et al., 2009), as well it has been found in rifampicin
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TABLE 2 | Mutations associated with resistance to first- and second-line drugs detected in the M. tuberculosis strains in study.
Strain ID Mutations
INH RIF AMK/CAP AMK CAP OFX
inhA prom inhA ORF katG rpoB RRDR rrs 1400 region eis prom tlyA gyrA QRDR
SUSCEPTIBLE
H37Rv wt wt wt wt wt wt wt wt
MtbPT1 wt wt wt wt wt wt wt wt
MtbPT2 wt wt wt wt wt wt wt wt
INHR
MtbPT3 wt wt S315T wt wt nt nt wt
MtbPT4 C-15T wt wt wt wt nt nt wt
RIFR
MtbPT5 wt nt wt S531L wt wt wt wt
MtbPT6 wt nt wt S531L wt nt nt wt
OFXR
MtbBR1 wt nt wt wt wt nt nt D94N
Poly-DR
MtbBR2 wt nt S315T D516Y wt nt nt A90V
MDR
MtbBR3 wt nt S315T S531L wt wt nt wt
MtbBR4 wt nt S315T S531L wt wt nt wt
MtbBR5 wt nt S315T S531L wt wt nt wt
MtbPT7 C-15T S94A wt S531L wt wt wt wt
MtbBR6 wt nt D735A S531L A1401G wt wt wt
MtbPT8 wt wt S315T S531L wt/A1401G* wt wt wt
XDR
MtbPT9 C-15T S94A wt S531L wt G-10A ins GT at pos 755/756 S91P
MtbPT10 C-15T I194T wt S531L A1401G wt wt D94A
MtbPT11 C-15T I194T wt S531L A1401G nt nt D94A
*Heteroresistance. AMK, amikacin; CAP, capreomycin; ID, identification; INH, isoniazid; MDR, multidrug resistant; nt, not tested; OFX, ofloxacin; ORF, open reading frame; Poly-DR,
poly-drug resistant; Prom, promoter; QRDR, quinolone resistance determining region; RIF, rifampicin; RRDR, rifampicin resistance determining region; wt, wild-type sequence; XDR,
extensively drug resistant.
susceptible strains (Somoskovi et al., 2006; Andres et al., 2014),
therefore a non-consensual genotype associated to resistance
important to be included and analyzed in the context of this
study.
Regarding second-line drugs, the MDR strains MtbBR6 and
MtbPT8 were additionally resistant to one second line-injectable
drug, and MtbBR2 was resistant to ofloxacin. MtbBR6 and
MtbPT8 harbored a mutation in rrs, A1401G, and in strain
MtbBR2 was found the A90V mutation in gyrA. MtbPT9,
MtbPT10, and MtbPT11 were classified as XDR. Strains
MtbPT10 and MtbPT11 harbored the rrs A1401G. This is the
most common mutation found in clinical isolates resistant to
second-line aminoglycosides (Cambau et al., 2015; Domínguez
et al., 2016). For MtbPT9, no mutation could be found in the rrs
gene. The resistance to amikacin was assigned to a mutation in
eis promoter and the resistance to capreomycin was attributed
to the insertion of a GT base pair at position 755/756 of the
tlyA gene. The mutation G-10A in the eis promoter region was
previously showed to be associated with resistance to kanamycin
(Zaunbrecher et al., 2009) and with low-level resistance to
amikacin (Perdigão et al., 2013). The insertion of a GT base
pair at position 755/766 of tlyA was previously showed to be
associated with capreomycin resistance (Perdigão et al., 2013).
Resistance to ofloxacin of these three strains was associated
with common mutations in gyrA at codons 91 and 94 (Table 2;
Cambau et al., 2015; Domínguez et al., 2016). MtbBR1 exhibited
monoresistance to ofloxacin associated with a mutation in gyrA,
D94N.
Summing up, we have selected a representative and
diverse sample of clinical strains of M. tuberculosis from two
geographical distinct areas harboring the most representative
gene mutations in known drug targets, accounting for
clinical resistance to the most important first- and second-
line antituberculosis drugs. As per the most commonly accepted
dogma about the mechanisms accounting for drug resistance
in M. tuberculosis, the sole cause of the resistance levels
noticed in these strains are expected to be derived exclusively
from the diminished affinity of the mutated genes toward the
respective antibiotic (Zhang and Yew, 2009; Domínguez et al.,
2016).
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Quantification of the Drug Resistance
Levels in the Presence of Efflux Inhibitors
Secondly, we quantified the drug resistance levels of the strains
toward the antibiotics in study. For this purpose, the MICs of
the antibiotics and efflux inhibitors were determined for each
strain and the results are presented in Table 3. The MICs of the
efflux inhibitors were found to be quite homogenous among the
seven groups of strains. Conversely, the MICs of the antibiotics
showed that for the samemutation different resistance levels were
present. Therefore, we hypothesize that the different resistance
levels presented for the same genotype are due to different levels
of active efflux of the antibiotics. The existence of active efflux
was evaluated indirectly through the reduction of the resistance
levels of the antibiotics in the presence of the efflux inhibitors
verapamil, thioridazine and chlorpromazine by qDST and MIC
determination (Table 4).
Resistance Levels for Isoniazid
Eleven out of 12 strains resistant to isoniazid presented high-level
resistance (R≥ 1µg/ml). Efflux activity was detected in all except
MtbPT4, the only strain that showed low-level resistance. The
low-level resistance presented by this strain was attributed to
the single C-15T mutation, which results in inhA overexpression
and leads to titration of isoniazid and consequent mild increased
resistance. For the remaining 11 strains, the resistance levels were
reduced from high- to low-level (R < 1 µg/ml) in 4/11 with
verapamil; 2/11 with thioridazine; and 5/11 with chlorpromazine.
For the strains that do not reached low-level resistance, the MICs
were reduced to 3 µg/ml. In respect to the efflux levels of the
strains that harbored mutations in katG, the results showed that
they have less efflux activity than those presenting mutations in
inhA. Strains MtbPT7, MtbPT9, MtbPT10, and MtbPT11 have
the C-15Tmutation and additionally have a mutation in the inhA
ORF contributing to their high-level resistance to isoniazid, as
previously shown (Machado et al., 2013). The level of resistance
of these strains was reduced with the efflux inhibitors to values
always above that conferred by the single mutation in the inhA
promoter (0.4 µg/ml), suggesting that the net resistance level
conferred by inhA double mutations (promoter plus ORF) bears
also a strong contribution from efflux. Noteworthy is that the
strain MtbBR6 with a rare mutation in katG presents high-
level resistance that could be reduced by all inhibitors tested.
TABLE 3 | MIC of antibiotics and efflux inhibitors for the M. tuberculosis strains studied.
Strain ID MIC (µg/ml)
Antibiotics* Efflux inhibitors
INH RIF AMK CAP OFX VP TZ CPZ
SUSCEPTIBLE
H37Rv 0.1 1 1 2.5 1 256 15 30
MtbPT1 0.1 1 1 2.5 1 256 30 30
MtbPT2 0.1 1 1 2.5 1 256 15 30
INHR
MtbPT3 10 1 1 2.5 1 256 15 30
MtbPT4 0.4 1 1 2.5 1 256 15 30
RIFR
MtbPT5 0.1 256 1 2.5 1 256 15 30
MtbPT6 0.1 512 1 2.5 1 256 15 30
OFXR
MtbBR1 0.1 1 1 2.5 32 128 15 30
Poly-DR
MtbBR2 3 1 1 2.5 10 256 15 30
MDR
MtbBR3 10 320 1 2.5 1 256 15 15
MtbBR4 10 640 1 2.5 1 256 15 15
MtbBR5 10 160 1 2.5 1 128 15 15
MtbPT7 3 320 1 2.5 1 256 15 30
MtbBR6 80 80 320 5 1 128 30 30
MtbPT8 20 320 40 25 1 256 15 30
XDR
MtbPT9 20 80 4 25 10 128 15 30
MtbPT10 3 320 640 25 10 256 15 30
MtbPT11 3 320 640 50 10 256 15 30
*The lowest concentration tested corresponded to the critical concentration for each antibiotic (see Section Materials and Methods for details). AMK, amikacin; CAP, capreomycin; CPZ,
chlorpromazine; INH, isoniazid; MDR, multidrug resistant; OFX, ofloxacin; Poly-DR, poly-drug resistant; RIF, rifampicin; TZ, thioridazine; VP, verapamil; XDR, extensively drug resistant.
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The difference between the levels of resistance caused by this
mutation compared with those presented by the strains with the
katG S315T mutation may be due to fitness cost. It is known
that the mutation S315T has no fitness cost for the bacteria
(Gagneux, 2009) being the most frequent and successful katG
mutation accounting for isoniazid resistance worldwide (Seifert
et al., 2015). Efflux activity is minimal in strains that bare this
mutation since they don’t need efflux to cope with the presence
of isoniazid. These results confirm our previous findings that
the high-levels of resistance associated with mutations in inhA
have an increased component of efflux when compared with M.
tuberculosis strains with high-level resistance associated with the
katG S315T mutation (Machado et al., 2016).
Resistance Levels for Rifampicin
All the strains resistant to rifampicin presented high-level
resistance (R≥ 20 µg/ml). Efflux activity was detected in all with
all the inhibitors although with different efficiencies (Table 4).
The resistance levels toward rifampicin were significantly
reduced in the presence of verapamil (11/11), thioridazine
(4/11), and chlorpromazine (9/11). To assess the contribution of
efflux activity to the borderline susceptibility toward rifampicin
in MtbBR2, this strain was evaluated for susceptibility to
rifampicin in the presence of efflux inhibitors. Notably, the
borderline susceptibility was reversed with all inhibitors tested
to concentrations well below the critical concentration (Table 4).
We hypothesize that the rpoB D516Y mutation is associated
with intermediate rifampicin susceptibility that has a strong
association with efflux activity. For all other strains, the results
demonstrated that efflux acts synergistically with mutations
associated with rifampicin resistance although the rpoB S531L
mutation is sufficient to produce high-levels of resistance to this
antibiotic.
Resistance Levels for Amikacin and Capreomycin
The rrs A1401G is associated with high-levels resistance to
amikacin and capreomycin (Sirgel et al., 2011; Du et al., 2013).
Strains MtbBR6, MtbPT8, MtbPT10, and MtbPT11 share the
mutation A1401G. Efflux activity was detected in all except
in MtbBR6 (Table 4). Amikacin resistance levels of MtbPT10
and MtbPT11 were reduced with chlorpromazine from 640 to
40 µg/ml, a 16-fold reduction. However, although significant,
this reduction was not sufficient to reach amikacin low-level
resistance. The low-level resistance to amikacin of MtbPT9 was
due to a mutation in the eis promoter region and no reduction
was obtained with any of the inhibitors tested. Amikacin is
acetylated by Eis (Zaunbrecher et al., 2009). We hypothesize
that the structural modification of the drug impairs substrate
recognition and consequently its efflux by the efflux pumps but
more studies are required to demonstrate this. Strain MtbPT8
showed the lowest level of resistance to amikacin (40 µg/ml)
when compared with the other three amikacin resistant strains
with the rrs A1401G mutation. In this strain, the resistance
to amikacin was reversed with all the efflux inhibitors. This
strain is heteroresistant to amikacin, i.e., the strain population
is composed by an amikacin-susceptible subpopulation and an
amikacin-resistant subpopulation. Heteroresistance was detected
by reverse hybridization using theMTBDRsl assay. The detection
of mixed genotypes (hybridization with both wild-type and
resistant probes) in the same sample is dependent on the
concentration of each individual genotype. Zhang et al. (2013)
showed that the low-level of amikacin resistance presented by
heteroresistant strains in mainly due to the presence of the drug
susceptible population. This data indicates that the proportion of
the amikacin-resistant subpopulation is reduced comparatively
with the amikacin-susceptible subpopulation only conferring
low-level resistance. Therefore, the resistant population during
the acquired resistance pathway could be highly reduced in
the presence of efflux inhibitors, further demonstrating the
contribution of efflux to the establishment and stabilization of
mutations in a M. tuberculosis population under drug selection
(Machado et al., 2012; Schmalstieg et al., 2012).
Of the five strains resistant to capreomycin, four have the
mutation rrsA1401G (including the heteroresistant one) and one
presented a mutation in tlyA. With the exception of MtbBR6 all
the others presented high-level resistance toward this antibiotic.
The low-level resistance presented by MtbBR6 was reversed
with thioridazine and chlorpromazine. Capreomycin resistance
was reduced to low-level with verapamil (2/5), chlorpromazine
(2/5), and thioridazine (1/5). Interesting, capreomycin resistance
could not be reduced with any of the inhibitors tested in the
heteroresistant strain (MtbPT8) for which amikacin resistance
was reversed. Since cross-resistance between amikacin and
capreomycin is due to the mutation rrs A1401G, this unexpected
result may be explained by the existence of an unknown
mechanism associated with capreomycin resistance in this strain.
We search for mutations in tlyA that could co-exist with the rrs
mutation but none was found and this subject will be explored in
future work. It was not possible to reduce capreomycin resistance
in MtbPT9 which is associated with an insertion mutation
in tlyA. Capreomycin is methylated by TlyA and the loss of
methyltransferase activity due to the presence of mutations in
tlyA reduces susceptibility to this drug (Maus et al., 2005). Similar
to that observed for Eis, we can speculate that the alteration of
an essential pathway necessary for the binding of the drug to the
target will hamper the substrate recognition and consequently its
efflux by the mycobacterial efflux pumps.
Resistance Levels for Ofloxacin
Resistance to fluoroquinolones involve mainly mutations in
gyrA and the most common are at positions 90, 91, and 94
which are associated with high-level resistance (Cambau et al.,
2015). All the strains resistant to ofloxacin presented high-level
resistance (Table 4). Resistance to ofloxacin of strains MtbPT9
to MtbPT11 could not be reduced with any of the inhibitors
tested. On these strains, resistance could be solely attributed to
the mutations S91P and D94A on gyrA. For MtbBR1 only basal
efflux activity could be detected (Table 4). Contrary, ofloxacin
resistance of strain MtbBR2 was reversed by thioridazine and
chlorpromazine to levels below the critical concentration and
reduced from 10 to 2 µg/ml with verapamil (Table 4). This
strain harbored the gyrA A90V mutation whose role in ofloxacin
resistance is controversial. The gyrAA90Vmutation was recently
associated with borderline levels of resistance toward ofloxacin,
Frontiers in Microbiology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 711
Machado et al. Efflux Resistance Levels in M. tuberculosis
i.e., the level of resistance can be close or below the critical
concentration of 1 µg/ml (Niward et al., 2016). In contrast,
Farhat et al. (2016) reported that strains with the gyrA A90V
mutation have a comparable effect on ofloxacin MIC as the
mutation D94A/G (1 µg/ml>MIC<10 µg/ml). Other studies
associate this mutation with ofloxacin resistance above 2 µg/ml
(Poissy et al., 2010; Cambau et al., 2015). Our results showed
that the A90V mutation can confer resistance up to 2 µg/ml and
that the remaining resistance presented has an efflux component
that can be reduced with an efflux inhibitor. This mutation have
also been found in strains harboring both mutated and wild-
type sequences, i.e., fluoroquinolone heteroresistant strains, or
in samples harboring two different strains (van den Boogaard
et al., 2011). The discrepancies noted between these studies
together with the evidence that efflux in linked to this mutation
may indicate that the mutation gyrA A90V is associated with
intermediate resistance to ofloxacin in strong association with
fluoroquinolone efflux that increases the levels of resistance,
nevertheless, more studies are needed to support this hypothesis.
All other gyrA mutations detected were sufficient to produce
stable ofloxacin resistance demonstrating that efflux has little
contribution toward ofloxacin resistance when these mutations
are present.
Determination of the Intrinsic Efflux
Capacity of the M. tuberculosis Strains
Thirdly, to confirm the existence of active efflux systems on
these strains we have evaluated their ability to efflux ethidium
bromide, a fluorescent efflux substrate, by real-time fluorometry
(Paixão et al., 2009; Viveiros et al., 2010; Machado et al.,
2012). To perform these assays, one representative of each
drug resistant group was selected: MtbPT3, monoresistant
to isoniazid; MtbPT5, monoresistant to rifampicin; MtbBR1,
monoresistant to ofloxacin; MtbPT7, multidrug resistant, and
MtbPT11, extensively drug resistant (Figure 1). M. tuberculosis
H37Rv and MtbPT1 were included as representatives of drug
susceptible strains. The strains were incubated with ethidium
bromide at the equilibrium concentration determined for each
strain and verapamil at half MIC (see Table 3 for MIC values)
for 1 h. After this period, verapamil was washed out from the
solution, the cells were assayed with glucose, as energy source,
and without glucose, and their efflux capacity was measured
by fluorometry (see Section Materials and Methods for details).
As can be observed in Figure 1, efflux of ethidium bromide
was detected in all these strains (colored curve), although
with different efficiencies, which was inhibited in presence of
verapamil at half MIC (black dashed line). It was also noted
that the efflux of ethidium bromide is not affected by the
presence of glucose (compare gray curve with the colored curve
on each graph) which shows that the external energization
of the cells is not necessary to guarantee an optimal efflux
activity in M. tuberculosis, a common requirement for efficient
efflux in Gram-negative bacteria (Paixão et al., 2009; Viveiros
et al., 2010). The assays performed with the susceptible strains
further confirmed that efflux activity in M. tuberculosis is an
intrinsic characteristic of susceptible and drug resistance strains
FIGURE 1 | Assessment of efflux activity on the M. tuberculosis strains in study. Ethidium bromide was used at the equilibrium concentration for each strain
as follows: 0.25 µg/ml for H37Rv, MtbPT1, MtbPT5, MtbPT7, and MtbPT11; 0.5 µg/ml, MtbPT3; and 1 µg/ml, MtbBR1; verapamil was tested at half MIC.
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(Machado et al., 2012). The different degrees of efflux activity
observed, e.g., MtbBR1 presented increased efflux activity and
MtbPT1 presented reduced efflux activity compared with the
other strains, may be related to the different environmental
conditions to which these strains were subject in the clinical
setting. To further confirm that the efflux activity of these strains
could be inhibited in the presence of the efflux inhibitors, we
performed ethidium bromide accumulation assays in presence
of verapamil, thioridazine, and chlorpromazine (Figure 2) and
determined the RFF index (Table 5). The RFF index is a measure
of how efficient is the inhibitor in promoting intracellular
accumulation of ethidium bromide. The results showed that
the three inhibitors were capable to increase the ethidium
bromide accumulation in all the tested strains (Table 5). The
most efficient efflux inhibitor in these assays was verapamil
(6/7), followed by thioridazine (2/7), and chlorpromazine (1/7).
The results demonstrated that these compounds are able to
promote intracellular accumulation of ethidium bromide on M.
tuberculosis susceptible, monoresistant and MDR/XDR strains,
clearly putting in evidence that active efflux is inhibited by these
compounds.
Effect of Antibiotics on Efflux Pump Gene
Expression
To further corroborate these findings we analyzed the
transcriptional profile of putative efflux pumps described
in the literature as being associated with antibiotic resistance
phenotypes ofM. tuberculosis strains (Viveiros et al., 2012; Black
et al., 2014; da Silva et al., 2016). RT-qPCR was done for six genes
previously shown to be overexpressed in response to antibiotic
exposure (Machado et al., 2012, 2016). The results showed the
occurrence of significant changes in the expression levels in all
strains upon exposure to the antibiotics except in the susceptible
H37Rv strain (Figure 3). Concerning the monoresistant
strains, in MtbPT3 exposed to isoniazid only efpA was found
overexpressed. In strain MtbPT5 exposed to rifampicin, from the
six genes tested, four were found overexpressed namely mmpL7,
mmr, p55, and efpA. The ofloxacin resistant strain MtbBR1 when
exposed to ofloxacin showed significant overexpression all the
genes tested (≥two-fold expression). The MDR and XDR strains
were exposed to rifampicin or isoniazid and similar patterns
were observed. Three to six genes were overexpressed upon
exposure to isoniazid or rifampicin. P55 showed the highest level
FIGURE 2 | Evaluation of the effect of efflux inhibitors on the accumulation of ethidium bromide on the M. tuberculosis strains in study. Ethidium
bromide (EtBr) was used at the equilibrium concentration for each strain as follows: 0.25 µg/ml for H37Rv, MtbPT1, MtbPT5, MtbPT7, and MtbPT11; 0.5 µg/ml,
MtbPT3; and 1 µg/ml, MtbBR1; each efflux inhibitor was tested at half MIC.
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TABLE 5 | RFF based on the accumulation of ethidium bromide for the
M. tuberculosis strains in the presence of efflux inhibitors.
Strain RFF of the inhibitors
Verapamil Thioridazine Chlorpromazine
H37Rv 1.69 ± 0.09*** 0.82 ± 0.15* 0.81 ± 0.03**
MtbPT1 0.86 ± 0.03** 0.18 ± 0.06* 0.13 ± 0.02*
MtbPT3 1.68 ± 0.24** 0.78 ± 0.02* 0.45 ± 0.02*
MtbPT5 1.17 ± 0.08** 0.24 ± 0.09 0.26 ± 0.06
MtbBR1 1.76 ± 0.21 1.39 ± 0.32 0.88 ± 0.13
MtbPT7 2.17 ± 0.01* 0.98 ± 0.02* 0.67 ± 0.04*
MtbPT11 2.00 ± 0.21** 1.14 ± 0.11* 1.04 ± 0.03**
Ethidium bromide was used at the equilibrium concentration for each strain as follows:
0.25 µg/ml, H37Rv, MtbPT1, MtbPT5, MtbPT7, and MtbPT11; 0.5 µg/ml, MtbPT3; and
1 µg/ml, MtbBR1; the inhibitors were tested at half MIC. The effect of the inhibitors on
the accumulation of ethidium bromide was interpreted as follows: RFF values above
zero indicated that the cells accumulate more ethidium bromide under the condition
used than those of the control (non-treated cells). Values in boldface (above 1) indicated
enhanced accumulation of ethidium bromide in the presence of the efflux inhibitors. Each
assay was performed in triplicate and the results presented correspond to the average
of three independent assays plus standard deviation (±SD). The results were considered
significant when *P < 0.05; and highly significant when **P < 0.01 and ***P < 0.001.
of expression on both strains and for both antibiotics. Overall,
EfpA was overexpressed in all strains independently of the
antibiotic to which it was exposed. Contrary, Rv2459 was found
overexpressed only in the ofloxacin monoresistant strain exposed
to ofloxacin. For the remaining efflux pumps analyzed we could
not associate an antibiotic to the overexpression of a particular
efflux pump. We have observed a general pattern of efflux pump
gene expression upon the exposure to the antibiotics.
M. tuberculosis Growth Kinetics in the
Presence of Antibiotics and Efflux
Inhibitors
If efflux really contributes to the overall drug resistance level seen
above, the delay in the growth of each drug resistant strain, due
to the stress imposed by the combination of an antibiotic plus
an efflux inhibitor at subinhibitory concentrations, will render
them more susceptible to the effect of the antibiotic. To test
this hypothesis, we performed qDST for selected M. tuberculosis
strains and investigated the TTD of growth in the presence
and absence of the efflux inhibitors to attain clinical correlation
(Machado et al., 2016).
The results showed a delay between the TTD of the
tube containing the antibiotic plus an efflux inhibitor and
the tube containing only the antibiotic ranging from 1 to
63 days depending on the antibiotic concentration and the
drug combination (Supplementary Tables 2–4). Rifampicin at
1 µg/ml in combination with the efflux inhibitors showed
a delay in the TTD of strain MtbPT11 of 48 h in the
presence of thioridazine, corresponding to a potentiation of
rifampicin activity of 63.23% when compared with rifampicin
only. Similarly, in the presence of verapamil or chlorpromazine,
the delay was 72 h corresponding to a potentiation of rifampicin
activity of 95.81 and 96.77%, respectively. Noteworthy, this
strain became susceptible to rifampicin at 20 µg/ml in
the presence of verapamil (Figure 4) and chlorpromazine,
with a delay in the TTD of 386 and 195 h, respectively
(Supplementary Table 2). In Figure 5 is presented the qDST
of isoniazid for the same strain and it can be observed the
increasing of the TTD at each concentration of isoniazid
in the presence of half MIC of verapamil. These results
showed that the antibiotic activity is clearly potentiated by the
efflux inhibitors as demonstrated by the delay on the TTD
of growth although, as seen previously, they do not reach
susceptibility levels due to the antibiotic-target mutations they
carry.
DISCUSSION
Whilst drug resistance inM. tuberculosis has long been associated
with the development of mutations in the genes that code
for the drug targets, efflux pump activity was only recently
recognized to play a significant role in the development of drug
resistant phenotypes in M. tuberculosis. Several recent studies
have demonstrated the importance of the overexpression of efflux
pump genes in MDR and XDR M. tuberculosis clinical strains
(Calgin et al., 2013; Coelho et al., 2015; Li et al., 2015a; Yamchi
et al., 2015; Kanji et al., 2016; Machado et al., 2016; Oh et al.,
2017), in rifampicin monoresistant strains (Li et al., 2015b), or
in the H37Rv susceptible strain after exposure to drugs (Garima
et al., 2015; Caleffi-Ferracioli et al., 2016). Nevertheless, most of
these studies are based on the simple assessment and evaluation
of the levels of expression of M. tuberculosis efflux pump genes,
and few have determined the effect of efflux inhibitors on the
MICs of the antituberculosis drugs and have quantified the
activity of the overexpressed efflux systems. Therefore, further
studies are needed to explore the contribution of the overactivity
of efflux pumps to the resistance levels inM. tuberculosis strains.
In a previous work, we presented a model on how multidrug
resistance develops in tuberculosis patients, the role of efflux
pumps on the development of isoniazid resistance once exposed
to the critical concentration of this antituberculosis drug and
how these events determine the basis of acquired multidrug
resistance (Machado et al., 2012). From that work two questions
were raised: (i) what is the role played by the efflux systems
in M. tuberculosis strains that already carry mutations in the
drug target genes? and (ii) do they respond in the same way to
the drug pressure despite the presence of a mutation? In this
work, we selected a panel of M. tuberculosis strains presenting
different phenotypes and genotypes to study the relationship
between the effects of efflux inhibitors on the levels of resistance
of the main antituberculosis drugs, the overexpression of efflux
pumps upon drug pressure, and the presence of active efflux
systems. This study was designed and executed to provide a
simple and comprehensive demonstration that drug resistance in
M. tuberculosis is a combination between efflux and the presence
of a mutation in the drug target gene, a controversial subject in
debate for many years (Jarlier and Nikaido, 1994; Louw et al.,
2009; da Silva et al., 2011, 2016; Machado et al., 2012; Schmalstieg
et al., 2012; Viveiros et al., 2012).
Frontiers in Microbiology | www.frontiersin.org 12 April 2017 | Volume 8 | Article 711
Machado et al. Efflux Resistance Levels in M. tuberculosis
FIGURE 3 | Quantification of the relative mRNA expression levels of a panel of efflux pump genes. Strains were grown in MGIT tubes for the MGIT 960
system in the presence of half MIC of each antibiotic as follows: MtbPT3 was exposed to isoniazid; MtbPT5 was exposed to rifampicin; MtbBR1 was exposed to
ofloxacin; H37Rv, MtbPT7, and MtbPT11 were exposed to isoniazid or rifampicin. The relative expression of the efflux pump genes was assessed by comparison of
the relative quantity of the respective mRNA in the presence of an antibiotic to the non-exposed strain. A level of relative expression equal to 1 indicates that the
expression level was identical to the strain that was being compared (gray dashed line in the graphs). Genes showing expression levels above 1 were considered to be
expressed; genes showing expression levels above two were considered to be significant overexpressed. The results were considered significant when *P < 0.05;
and highly significant when **P < 0.01 and ***P < 0.001.
First we analyzed the effect of verapamil, thioridazine and
chlorpromazine, known inhibitors of M. tuberculosis efflux
pumps, on the resistance levels of first- and second-line drugs
against a panel of monoresistant, MDR and XDRM. tuberculosis
strains. The results obtained demonstrated that the resistance
levels of the M. tuberculosis clinical strains toward the first-
and second-line antibiotics studied could be reduced by an
efflux inhibitor, independently of the genotype of the strains,
demonstrating that the efflux pump inhibitors could be useful in
combination with the standard antituberculosis therapy. These
results showed that the drug resistant level observed on these
strains is a combination between the efflux activity and the
mutation in a drug resistance target. With the concentrations of
the efflux inhibitors that we tested (half MIC), we can only aim
to reduce the efflux component but the resistance component
due to the mutation remains untouched. It is not plausible that
a compound, whose main function is the inhibition of efflux
activity, could reverse the antibiotic resistance in the presence
of a mutation associated with high-level resistance. Since all
these strains presented mutations associated with high-level drug
resistance, these antibiotics are useless in these cases. Although
the degree of synergism does not reach full susceptibility, the
reduction of the MIC value of the antibiotics to values close or
within the serum concentration can improve therapy outcomes
demonstrating the possible usefulness of the efflux inhibitors as
helper-compounds of antibiotic activity in tuberculosis treatment
(Böttger, 2011; Machado et al., 2012; Viveiros et al., 2012; da
Silva et al., 2016). Furthermore, it is described that the antibiotics
can penetrate and concentrate within macrophages (Prokesch
and Hand, 1982) increasing, by this manner, their effective
concentrations.
We also demonstrated that the efflux inhibitors verapamil,
thioridazine, and chlorpromazine are able to promote the
intracellular accumulation of ethidium bromide, a broad range
substrate for efflux pumps (Blair and Piddock, 2016), on the
M. tuberculosis strains, clearly putting in evidence that active
efflux is inhibited by these compounds. At the present, we do not
know the exact mechanism by which these compounds inhibit
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FIGURE 4 | Quantitative drug susceptibility testing of rifampicin for the
strain MtbPT11, in the presence or absence of verapamil. Quantitative
drug susceptibility testing of isoniazid was conducted using the BACTEC 960
system and the Epicenter V5.80A software equipped with the TB eXIST
module. In the Figure is presented the result of the testing for the strain
MtbPT11 at 20 µg/ml of rifampicin alone (full orange curve) and rifampicin at
20 µg/ml in the presence of verapamil at half MIC (dashed orange curve).
Verapamil alone does not inhibit the growth of the strain (gray curve). Absolute
control is given by the dotted blue curve (undiluted strain 1:1) and the
proportional control is given by the continuous blue curve (strain diluted
1:100). At the time of growth of the proportional growth control (GU =
400—black dashed line), the comparison between this tube and the tubes
containing the drugs(s) was performed. If the GU of the tubes containing the
drug were >100 (red dashed line), they were considered to be resistant to that
concentration. If the GU of the tube containing the drug was <100 they were
considered susceptible.
the efflux activity in M. tuberculosis. It has been hypothesized in
several studies that these efflux inhibitors affect M. tuberculosis
membrane energetics and that they inhibit efflux by inhibiting
the energy required for the pumps function (Black et al., 2014;
Pule et al., 2016; da Silva et al., 2016). Due to the paucity of new
antituberculosis drugs in the tuberculosis drug discovery pipeline
and the increasing of drug resistant tuberculosis there is an urgent
need for the development of new drugs and the implementation
of new therapeutic strategies. The use of compounds that have
the ability to inhibit mycobacterial efflux pumps promoting the
retention of the co-administered antibiotics that are subject to
efflux will obviously improve the efficacy and will extend the
clinical utility of the existing antibiotics. In this sense, in the last
years, various compounds have been developed and described
as putative efflux pump inhibitors, e.g., verapamil analogs were
shown to be effective antituberculosis inhibitors being able to
reduce the level of resistance to rifampicin by binding to the efflux
pump Rv1258c (Singh et al., 2014); thioridazine derivatives have
demonstrated to potentiate the antituberculosis drug activity
against M. tuberculosis in vitro and ex vivo (Pieroni et al., 2015),
and hybrid efflux pump inhibitors, combining the activities of
verapamil and thioridazine, were also shown to possess in vitro
FIGURE 5 | Quantitative drug susceptibility testing of isoniazid for the
strain MtbPT11, in the presence or absence of verapamil. Quantitative
drug susceptibility testing of isoniazid was conducted using the BACTEC 960
system and the Epicenter V5.80A software equipped with the TB eXIST
module. Absolute control is given by the dotted blue curve (undiluted strain
1:1) and the proportional control is given by the continuous blue curve (strain
diluted 1:100). The orange, yellow, pink, and green full curves correspond to
the growth curves of the strain in the presence of only isoniazid; the respective
colored dashed curves corresponded to the growth curves of the strain in the
presence of isoniazid and verapamil; Verapamil alone does not inhibit the
growth of the strain (gray curve). At the time of growth of the proportional
growth control (GU = 400—black dashed line), the comparison between this
tube and the tubes containing the drugs(s) was performed. If the GU of the
tubes containing the drug were >100 (red dashed line), they were considered
to be resistant to that concentration. If the GU of the tube containing the drug
was <100 they were considered susceptible. Isoniazid was tested at 0.1, 1, 3,
and 10 µg/ml with and without half MIC of verapamil.
antituberculosis activity and intracellular activity in macrophages
(Kumar et al., 2016).
Next, we analyzed the expression levels of five putative efflux
pumps upon exposure to the antibiotics in the H37Rv susceptible
strain, and in the monoresistant, MDR and XDRM. tuberculosis
clinical isolates. The efflux pump genes mmr, mmpL7, Rv1258c,
p55, and efpA were shown to be overexpressed in presence
of antibiotics demonstrating the contribution of these efflux
pumps to the resistance phenotype of the strains studied, with
the exception of the H37Rv strain. We have noticed a general
overexpression of almost all efflux genes studied upon exposure
to the antibiotics in the drug resistant strains independently
on the genotype of the strains. Indeed, when we look to the
substrate specificity of each of the M. tuberculosis efflux pumps
described in the literature we cannot find a correlation between
a given substrate and a specific efflux pump (Supplementary
Table 1). These results indicated thatM. tuberculosis efflux pumps
are promiscuous in their activity as we cannot associate the
extrusion of drugs to a specific gene.Moreover, the RT-qPCR data
combined with the real-time fluorometry results showed that
the drug resistant clinical strains are more prompt to respond,
via an efflux-mediated response, to the antibiotics, whereas
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the susceptible H37Rv strain shows a less prompt detoxifying
response to the drugs to which it was exposed. Altogether, the
results obtained demonstrate that M. tuberculosis clinical strains
are primed to efflux noxious compounds and showed that efflux
pump induction is involved in the antibiotic resistance pattern
of the strains in study, reinforcing the validity of the hypotheses
that efflux contributes to the resistance level of these strains,
contributing also to their MDR phenotype.
We also showed that the TTD ofM. tuberculosis growth in the
MGIT 960 culture system in combination with qDST is a valuable
methodology to evaluate M. tuberculosis drug response and to
characterize the potency of drug combinations for personalized
treatment, especially for MDR/XDR-TB patient regimens. Since
the TTD and the inoculum concentration are inversely correlated
(Diacon et al., 2010; Bowness et al., 2015), this synergistic activity
can be highly beneficial during tuberculosis therapy, either in
drug susceptible or drug-resistant strains, allowing the antibiotic,
combined with the host’s immune system, to tackle in the most
effective way the infecting strain. This method allowed the
monitoring, on a real-time basis, of bacterial growth/survival
vs. growth inhibition by the comparison between the TTD of
growth of a given strain in the presence and absence of an efflux
inhibitor. The methodology used proved to be useful to study
the contribution of the efflux mechanisms to M. tuberculosis
drug resistance and simultaneously evaluate the efficacy of an
efflux inhibitor to decrease the level of resistance of a strain
to a given drug in the perspective of the development of
new therapeutic strategies for susceptible and drug resistant
tuberculosis, incorporating efflux inhibitors in the control and
prevention of drug resistance during therapy.
In conclusion, this study allowed us to show that the main
mechanisms associated with drug resistance in M. tuberculosis
correlates mutations in target genes with increased efflux and
that compounds that inhibit efflux activity can significantly
reduce the phenotypic level of such resistance. The level of
drug resistance in M. tuberculosis is a combination between the
presence of a mutation in the drug target genes and a general
stress response to the presence of noxious compounds that
regulates the intracellular level of a drug. The data obtained
in the presented study corroborated our previous findings
(Machado et al., 2012; Coelho et al., 2015) now tested on
a larger and diverse panel of M. tuberculosis clinical strains.
The demonstration that the efflux activity modulates the levels
of antibiotic resistance by complementing the resistance due
to target-gene mutations, is a very relevant finding in the
context of the ongoing discussion on the ability and clinical
reliability of sole molecular based detection of the target-gene
mutations as the future routine DST for M. tuberculosis
(Böttger, 2011; Domínguez et al., 2016; Pankhurst et al., 2016;
Schön et al., 2016). The use of efflux inhibitors as adjuvants
of the antituberculosis therapy may be a promise for the
development of new and shorter therapeutic strategies as they
may potentiate the activity of the current antituberculosis
drugs shortening the recommended 6 month treatment for
cure, they can increase the activity of drugs that are no
longer used due to the emergence of resistance, and they
may also be used to protect the activity and usefulness of
the new antituberculosis drugs from the development of drug
resistance.
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